<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02625948</url>
  </required_header>
  <id_info>
    <org_study_id>D141100000114002</org_study_id>
    <nct_id>NCT02625948</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid for Acute ICH Growth prEdicted by Spot Sign</brief_title>
  <acronym>TRAIGE</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Science and Technology of the People´s Republic of China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Municipal Science &amp; Technology Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ministry of Science and Technology of the People´s Republic of China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if computed tomography angiography can predict
      which individuals with intracerebral hemorrhage will experience significant growth in the
      size of the hemorrhage. For individuals who are at high risk for hemorrhage growth, the study
      will compare the drug Tranexamic acid to placebo to determine the effect and safety of on
      intracerebral hemorrhage growth
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Tranexamic Acid for Acute ICH Growth prEdicted by Spot Sign (TRAIGE) is a is a
      multicentre, randomized, placebo-controlled, double-blind, prospective, investigator-led,
      clinical trial of tranexamic acid within 6 hours of intracerebral hemorrhage in patients with
      contrast extravasation on CTA, 'the spot sign'. ICH patients within 6 hours of symptom onset,
      with the spot sign as a biomarker for ongoing hemorrhage, and no contraindications for
      antifibrinolytic therapy were enrolled in TRAIGE. The patient with a spot sign will be
      randomized to receive either the active treatment or placebo, the patient with no spot sign
      will be given regular treatment as observation. The trial is anticipated to complete in 36
      months from the first subject recruitment , with 240 subjects recruited. A Data and Safety
      Monitoring Board (DSMB) will regularly monitor safety during the study. The trial has been
      approved by IRB(Institutional Review Board) /EC(Ethics Committee) in Beijing Tiantan
      hospital, Capital Medical University.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hemorrhage growth</measure>
    <time_frame>24±2 hours</time_frame>
    <description>either &gt;33% or &gt;6 ml increase from baseline, adjusted for baseline ICH volume</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major thromboembolic events</measure>
    <time_frame>30±4 days</time_frame>
    <description>(1) acute myocardial ischemia; (2) acute cerebral ischemia; and (3) acute pulmonary embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Poor clinical outcome</measure>
    <time_frame>90±7 days</time_frame>
    <description>The Number of patients that is Death or major disability(mRS 4-6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>short-term outcome</measure>
    <time_frame>30±4 days</time_frame>
    <description>The Number of patients that with Modified Rankin Scale (mRS) 0-2 at 30±4 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other thromboembolic events</measure>
    <time_frame>90±7 days</time_frame>
    <description>Other thromboembolic events，such as venous thrombosis and other peripheral arterial embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death due to any cause</measure>
    <time_frame>90±7 days</time_frame>
    <description>Number of patients that is Death due to any cause by 90±7 days</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Absolute ICH growth volume</measure>
    <time_frame>24±2 hours</time_frame>
    <description>The absolute ICH growth volume compared with the baseline CT scan</description>
  </other_outcome>
  <other_outcome>
    <measure>Absolute IVH growth volume</measure>
    <time_frame>24±2 hours</time_frame>
    <description>The absolute IVH growth volume compared with the baseline CT scan</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>tranexamic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tranexamic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% NaCl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>observation(spot sign -)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>regular clinical treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <arm_group_label>tranexamic acid</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients presenting with an acute spontaneous hypertensive Intracerebral hemorrhage

          1. CTA evaluation can be accomplished within 6 hours of symptom onset, with &quot;spot sign&quot;
             positive in CTA original image

          2. Age range from 18 to 79 years

          3. Randomization can be finished and treatment can commence within 8 hours of symptom
             onset

          4. Informed consent has been received in accordance to local ethics committee
             requirements

        Exclusion Criteria:

          1. ICH known or suspected to be secondary to tumour, vascular malformation, aneurysm or
             trauma

          2. Infratentorial ICH

          3. Glasgow coma scale (GCS) total score of &lt;8

          4. ICH volume &gt;70 ml

          5. Parenchymal hemorrhage with ventricle involved, blood completely fills one lateral
             ventricle or more than half of both lateral ventricles

          6. Contraindication of CTA imaging (e.g. known or suspected iodine allergy or significant
             renal failure)

          7. Any history or current evidence suggestive of venous or arterial thrombotic events
             within the previous 6 months, including clinical, ECG, laboratory, or imaging
             findings. Clinically silent chance findings of old ischemia are not considered
             exclusion.

          8. Planned surgery for ICH

          9. Pregnancy or within 30 days after delivery, or during lactation

         10. Use of heparin, low-molecular weight heparin, or oral anticoagulation within the
             previous 1 week, with abnormal laboratory values

         11. Known allergy to tranexamic acid

         12. Prestroke modified mRS score of &gt;2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Liping Liu, MD</last_name>
    <phone>8610-67098368</phone>
    <email>lipingsister@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aviation General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Fangshan District Liangxiang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Haidian hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Huairou District Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Shunyi Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Tian Tan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liping Liu, MD</last_name>
      <phone>8610-67098368</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kailuan general hospital</name>
      <address>
        <city>Tangshan</city>
        <state>Hebei</state>
        <zip>063000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tangshan gongren hospital</name>
      <address>
        <city>Tangshan</city>
        <state>Hebei</state>
        <zip>063000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tangshan people's hospital</name>
      <address>
        <city>Tangshan</city>
        <state>Hebei</state>
        <zip>063000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2015</study_first_submitted>
  <study_first_submitted_qc>December 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2015</study_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ministry of Science and Technology of the People´s Republic of China</investigator_affiliation>
    <investigator_full_name>Liping Liu</investigator_full_name>
    <investigator_title>Professor of Neurology and Stroke Center, Beijing Tiantan Hospital, Capital Medical University</investigator_title>
  </responsible_party>
  <keyword>Intracerebral Hemorrhage</keyword>
  <keyword>tranexamic acid</keyword>
  <keyword>spot sign</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

